Emergent BioSolutions kündigt FDA-Zulassung für Änderung bei Lagerbedingungen und Produktionsverlagerungen für seinen Cholera-Impfstoff an

NEXT STORY
AB Science fournit un résumé de la conférence web qui s’est tenue le 5 juin 2019
PREV STORY
Bavarian Nordic Reports Positive Result from ongoing Phase 2 Trial Evaluating BN-Brachyury in Chordoma
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

DIAGNOS presents a technological showcase at the CHUM with the opening of an automated diabetic retinopathy screening clinic assisted by AI (Artificial Intelligence) with financial support of the Québec government

BROSSARD, Quebec, June 05, 2018 (GLOBE NEWSWIRE) -- DIAGNOS inc. (“DIAGNOS” or the “Company”) ...

author_avatar
NASDAQ Market News

Creation of novel medicines and better patient care for the future in an ecosystem

 ORION CORPORATION                    PRESS RELEASE                 17 SEPTEMBER 2018 Creation of novel medicines and better patient ...

author_avatar
NASDAQ Market News

Hemispherx Biopharma Issues Letter to Stockholders

Business Update and Apple iOS Stocks AdvisoryOCALA, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- ...

author_avatar
NASDAQ Market News